Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
CD388 is administered as a single 450-milligram subcutaneous dose in adults and adolescents
Surgical site infections and antimicrobial resistance remain major challenges globally
A key highlight will be Brenntag’s qualified amino acids portfolio
The Eurasian Patent Organization (EAPO) has granted Patent, protecting the company’s sublingual delivery technology for anticancer drugs used to treat autoimmune and neurodegenerative diseases
Subscribe To Our Newsletter & Stay Updated